Juvenescence Limited is a British Virgin Islands-based holding company focused on investing in the field of human aging and longevity. With a commitment to developing therapeutics that aim to extend both lifespan and healthspan, Juvenescence has raised significant funding to create a comprehensive ecosystem targeting aging and age-related diseases. The company collaborates with leading scientists and research institutions to in-license compounds and form joint ventures, leveraging recent scientific advancements to produce evidence-based therapies. By addressing the biological causes of aging, Juvenescence aims to develop medical solutions that promote healthy aging, metabolic health, and brain health. Their efforts are positioned to have substantial implications across various sectors, including healthcare and insurance, as they seek to improve the quality of life for an aging population.
LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
Souvien Therapeutics
Venture Round in 2019
Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
BYOMass
Venture Round in 2019
BYOMass is developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses.
AgeX is a biotechnology company that develops novel therapeutics for age-related degenerative diseases. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.